Loading stock data…
$193.65+5.21 (+2.76%)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Revolution Medicines, Inc. in the Healthcare sector is trading at $193.65 with a market capitalization of $44.4B. Wall Street consensus targets $259.14 (23 analysts), implying a +33.8% move over the next 12 months. The stock is currently near its 52-week high of $224.31, remaining 28.6% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$505.13M↓ | -$445.22M↓ | -$361.63M↓ | -$315.27M↓ | -$264.71M |
| Net Income | -$644.37M↓ | -$453.82M↓ | -$364.89M↓ | -$305.21M↓ | -$247.79M |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as m...